Many published randomized clinical trials (RCTs) make claims for subgroup differences.
often comes from subgroup analyses reported in randomized clinical trials (RCTs). [3] [4] [5] [6] Considering that the results from individual subgroup tests are often misleading and can lead to withholding of treatment or provision of incorrect, ineffective, or harmful treatments, it is important to understand the credibility of subgroup effects reported in RCTs. Previous research suggests that subgroup analyses are often poorly conducted and reported. [5] [6] [7] [8] [9] For example, Wang et al 5 pointed out key problems in subgroup claims in published RCTs. First, most subgroup analyses in RCTs fail to provide basic statistical support for their claims. 5, [8] [9] [10] [11] The presence of a statistical effect in one subgroup but not the other does not constitute evidence of a subgroup effect, as many authors mistakenly believe; rather, the appropriate statistical approach for establishing a subgroup test is a formal test of interaction. 12 Second, trials often perform numerous subgroup analyses that are not prespecified or adjusted for multiple testing, which increases the probability of false-positive findings. 5, 6, 9 Third, most trials fail to randomize participants within subgroups (eg, stratified randomization), 5, 8, 9 which leaves more room for imbalanced confounders between treatment and control arms within subgroups. Collectively, these problems may affect the credibility of subgroup findings from RCTs. Previous studies 3, 8, 9 have assessed the credibility of subgroup differences reported anywhere in the text of RCTs but have not focused on those most likely to be credible (ie, those reported in the articles' abstracts). Presumably, authors are more careful and selective about reporting subgroup differences in abstracts because these claims are most visible to the research community. Furthermore, to our knowledge, no previous studies have attempted to evaluate the credibility of subgroup findings by checking to see if they are corroborated (eg, new studies producing the same results with the same experimental methods). Specifically, we were interested in examining how often subgroup findings with statistical support (a significant formal test result of interaction) from RCTs are corroborated by subsequent RCTs or meta-analyses. The widespread inability to replicate published research and the lack of replication in the biomedical literature highlight the importance of corroborating previous subgroup findings. [13] [14] [15] Herein, we used 2 samples of RCTs with subgroup claims anywhere in the text to answer 4 questions: (1) how often are subgroup claims (with or without statistical support) reported in the abstracts of RCTs? (2) how often do these subgroup claims have formal statistical support? (3) how often are the abstract subgroup claims with formal statistical support based on a subgroup stratification factor at randomization, preplanned, and based on analyses adjusted for multiple comparisons? and (4) how often are the abstract subgroup claims with statistical support corroborated by subsequent RCTs and meta-analyses?
Methods
Details about the study are available in the eAppendix in the Supplement. This study included no human participants (it is a meta-epidemiological survey based on summary data available to the public). For this reason, there was no need for institutional review board approval.
Identification of RCTs With Subgroup Claims
To identify a sample of RCTs with subgroup claims in the abstract, we analyzed RCTs with at least 1 subgroup claim from the Subgroup Analysis of Trials Is Rarely Easy (SATIRE) 3, 9, 16 and Discontinuation of Randomized Trials (DISCO) 8 study groups. The SATIRE and DISCO study groups previously investigated characteristics related to the reporting and validity of subgroup claims. Because both study groups had already compiled separate samples of RCTs, we were able to request data from the study authors and construct a new database consisting of only RCTs with at least 1 subgroup analysis. Study descriptions, additional definitions, and inclusion and exclusion criteria appear in the original SATIRE and DISCO publications. We used the same definition of a subgroup as both the SATIRE and DISCO study groups. We focused on subgroup differences that appeared in the abstract of an article, which are the most visible ones. We defined a subgroup effect as claimed if there was either a clear or an implied statement that the effects of an intervention (ie, experiment vs control) differed according to the presence of a subgroup variable. Detailed definitions can be found in the eAppendix in the Supplement. The RCTs from the SATIRE and DISCO studies classified as including a subgroup claim in the abstract are hereafter referred to as "index articles." We defined a subgroup finding as a subgroup claim with evidence of statistically significant heterogeneity across subgroup levels from an interaction test or where the authors qualitatively implied that there was evidence of such statistically significant heterogeneity. We defined a pure corroboration attempt as a subsequent RCT or meta-analysis with an analysis for the exact same subgroup findings as reported in the index article (ie, for same subgroup levels, interventions, outcomes, and study population). A subgroup
Key Points
Question How often are subgroup claims reported in the abstracts of randomized clinical trials supported by a statistically significant interaction test result and corroborated by subsequent randomized clinical trials and meta-analyses?
Findings In this meta-epidemiological survey, a minority of subgroup claims (46 of 117) in the abstract of randomized clinical trials were supported by their own data. Only 5 of these 46 subgroup findings had at least 1 subsequent corroboration attempt, and none of the corroboration attempts had a statistically significant P value from an interaction test.
Meaning Claims of subgroup differences in randomized clinical trials are typically spurious or chance findings.
finding was considered corroborated if a subsequent RCT or meta-analysis provided subgroup-level effect sizes that were in the same direction as those reported in the index article and had evidence of statistically significant heterogeneity across subgroup levels from an interaction test (P < .05).
Two reviewers (J.D.W. and P.G.S.) independently screened all index articles (n = 169) to determine the subset of the articles that made subgroup claims in the abstract. Three additional reviewers arbitrated all potential discrepancies (J.F.T., K.L.S., and J.P.A.I.).
Identification of Corroboration Attempts
We used Scopus, a large abstract and citation database of peer-reviewed literature, to search for English-language publications citing each of the eligible index articles with at least 1 subgroup finding (searches updated July 2016). Within Scopus, one can search for the title of a study and obtain a list of all of the articles citing the study of interest. One reviewer (J.D.W.) screened the title and abstract of all citing articles to determine the citing RCTs and meta-analyses. The RCTs and meta-analyses were downloaded and screened by 2 reviewers (J.D.W. and P.G.S.) for evidence of subgroup corroboration attempts. Three additional investigators (J.F.T., K.L.S., and J.P.A.I.) arbitrated any uncertainties.
Data Extraction
For each index article with at least 1 subgroup claim in the abstract, we recorded the first author, year of publication, journal, and sample size randomized. We also extracted the compared interventions, population assessed, and outcomes for each individual subgroup claim. We noted the total number of subgroup claims, the number of claims where a P value was provided from a test for interaction, the number of claims where a statistically significant P value from a test for interaction was reported, the number of claims where there was not enough information provided in the full text to formally test for subgroup heterogeneity, and the number of claims where there was a statement in the full text indicating a subgroup finding (eg, "the interaction term was statistically significant").
For claims without clear evidence of statistical heterogeneity, 2 reviewers (J.D.W. and P.G.S.) extracted the relative or absolute effect sizes, CIs, standard errors, or any other available data to calculate subgroup-level effect sizes and standard errors. When the index articles did not provide effect measures for the subgroups of interest, we used our best judgment to determine whether to calculate a relative or absolute effect measure, depending on the other effect measures reported in the index article. When the choice was unclear, we calculated relative effect measures because multiplicative scale interactions are more often assessed and reported based on logistic or Cox proportional hazards regression models in RCTs. [17] [18] [19] An online digitizer (WebPlotDigitizer; http://arohatgi .info/WebPlotDigitizer) was used to extract approximate values from figures. When exact calculations were not possible, 2 reviewers (J.D.W. and K.L.S.) discussed the information and determined if it was possible to approximate the P value for interaction with enough precision to confidently classify it as significant or not significant.
For individual RCTs and meta-analyses that attempted to corroborate the subgroup finding from the index article, we extracted the first author, journal, year of publication, and whether there was any overlap in authorship with the index article. When there were several meta-analyses attempting the same corroboration, we focused on the most inclusive one. For any meta-analysis citing an index article with a subgroup finding, we extracted the number of studies and number of participants included in the subgroup effect calculation, the number of studies included in the calculation of the average effect size at the subgroup level that were published after the index study, the overall summary effect size and 95% CI, and the summary effect size and 95% CI in each pertinent subgroup level. This information was used to reevaluate heterogeneity using data from all available individual trials.
After we implemented suggestions raised by peer reviewers, we also screened all index articles to determine how often the abstract subgroup claims with formal statistical support were based on a stratification factor at randomization; were prespecified in the abstract, methods, or results of the trials; and were based on analyses adjusted for multiple comparisons. Finally, we considered the possibility that the index articles themselves might be corroboration attempts of previously published subgroup findings. To evaluate this possibility, we determined whether index articles cited previous RCTs with similar subgroup findings (ie, for same comparison, outcomes, and subgroup levels and with a significant P value for interaction).
Statistical Analysis
Subgroup-level effect estimates and standard errors were entered into a software program (R, version 3.2.3; The R Project for Statistical Computing), and the metafor package was used to test for heterogeneity using Cochran Q test. 20 For any meta-analysis attempting to corroborate a subgroup finding, we extracted the available data and tested for interaction using Cochran Q test. Trial data were combined within each subgroup level based on the DerSimonian and Laird procedure for random effects. P values were 2-tailed.
Results

Search Findings
Among the 169 articles with a subgroup effect claimed anywhere in the text, there were 64 articles (37.9%) with at least 1 subgroup claim made in the abstract. In these 64 articles, a total of 117 individual abstract subgroup claims were made ( Figure) . Table 2 lists the characteristics of the 46 subgroup findings (ie, the subgroup claims with statistical support). For 13 (28.3%) of the 46 subgroup findings, the analyses were listed as prespecified in the abstract, methods, or results sections of the corresponding RCTs. Furthermore, it was evident that the language used to discuss prespecification (ie, preplanned, a priori, previously suggested, planned, and prespecified) and nonprespecification (ie, secondary, explanatory, preliminary, and post hoc) lacked consistency across studies. For 16 of the 46 subgroup findings (34.8%), the subgroup variable was used as a stratification variable during randomization. Only 1 subgroup finding was adjusted for multiple comparisons (the Bonferroni-Holm step-down procedure). Overall, the most common medical fields represented were cardiovascular (n = 7) and infectious disease (n = 5).
Frequency and Characteristics of Subgroup Claims
Frequency and Characteristics of Subgroup Findings
Corroboration of Subgroup Findings
Among the 46 subgroup findings, only 5 (10.9%) had at least 1 subsequent pure corroboration attempt by a meta-analysis or a Subgroup findings were subgroup claims with evidence of statistical significant heterogeneity (P < .05) across subgroup levels from an interaction test or where the authors qualitatively implied that there was evidence of such statistically significant heterogeneity.
b Some index articles had multiple subgroup analyses for different outcomes based on the same subgroup variable used as a stratification factor at randomization. There were 13 individual subgroup variables used as a stratification factor at randomization, ignoring multiple outcomes per study.
P < .05 from an interaction test, and the subgroup-level effect estimates based on meta-analyzed data were generally attenuated toward the null (relative risk, odds ratio, or hazard ratio of 1.0) compared with the index article. One of the full corroboration attempts is described in the Box for illustration, and the remaining descriptions can be found in the eAppendix in the Supplement. It should be noted that all SATIRE articles were published in 2007, and the DISCO articles with subgroup findings were published between 2002 and 2012. Three to four years may not be long enough for a new RCT to publish a corroboration attempt. We also found modified corroboration attempts (ie, different subgroup levels, interventions, outcomes, or study population) for 4 subgroup findings in 3 index articles. [30] [31] [32] Two index articles 30, 32 had citing meta-analyses; in both cases, the corroboration attempts used different subgroup definitions (changing from 3 subgroup levels to 2 subgroup levels). There were 2 findings from the same RCTs that had subsequent RCTs investigating similar treatment by insulin interaction status. However, none of these RCTs used insulin concentration at 30 minutes as the measurement of insulin status (eTable in the Supplement). Two index articles with subgroup findings 30, 31 mentioned and cited previous RCTs that had evaluated subgroup analyses for similar comparisons, outcomes, and subgroup levels and also had evidence of statistically significant interaction. These index articles could themselves be viewed as potential corroboration attempts. However, in one case, the outcome of mortality had been assessed at a different time point (day 28 instead of day 140). 33 In the other one, a different study population and different dietary interventions were involved. c Provided by the authors based on relative risk. Because the corroborating meta-analysis provided only information based on odds ratios, we also reevaluated the interaction from the index article based on odds ratios. The interaction P value was no longer statistically significant (P = .12).
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Box. Pure Corroboration Example
Index Study Description
A 2007 article 23 compared standard care with or without intravenous cooling for patients with nontraumatic cardiac arrest resuscitated by paramedics. The authors reported a subgroup claim for the secondary outcome of being discharged alive from the hospital: They reported that infield cooling improved hospital survival for patients with ventricular fibrillation but reduced survival for patients without ventricular fibrillation.
Calculation of P Value for Interaction
The authors of the 2007 article 23 did not report a P value for interaction, but we were able to calculate this statistic based on data available in the article. When we recalculated the effect sizes on the risk ratio scale, we found risk ratios for survival of 1.44 (95% CI, 0.84-2.44) for patients with ventricular fibrillation and 0.29 (95% CI, 0.07-1.29) for patients without ventricular fibrillation. We found that the P value for interaction achieved statistical significance (P = .048). The overall treatment effect for cooling was null (risk ratio, 1.20; 95% CI, 0.73-1.98).
Subgroup Corroboration Attempts
We identified 2 meta-analyses 26, 27 and 2 randomized clinical trials 28, 29 that attempted to corroborate the subgroup finding for the same outcome. We used information from both meta-analyses to identify individual studies. Three trials provided data for both subgroup levels. One trial provided data for only the ventricular fibrillation subgroup, and 1 trial provided data for only the non-ventricular fibrillation subgroup. The meta-analyzed risk ratios were also attenuated to the null, with risk ratios of 0.98 (95% CI, 0.88-1.09) for the ventricular fibrillation group and 1.13 (95% CI, 0.74-1.74) for the non-ventricular fibrillation group. The meta-analyzed P value for interaction was not statistically significant (P = .52). There was no overall treatment benefit (risk ratio, 1.02; 95% CI, 0.89-1.16) (eFigure in the Supplement).
Discussion
Our empirical evaluation of subgroup claims from the abstracts of RCTs revealed that most claims (71 [60.7%] of 117) failed to have underlying evidence of statistical significance based on a test for interaction. Formal testing for interactions is not done (or reported) routinely. In addition, most subgroup findings reported in the abstracts of RCTs fail to meet other best practices for subgroup tests, including prespecification, stratified randomization, and adjustment for multiple testing. Rarely are attempts made to corroborate statistically significant subgroup findings in subsequent trials and meta-analyses. Moreover, none of the subsequent meta-analyses or individual RCTs successfully corroborated the subgroup findings. When effect sizes were available (n = 3), we found that the effect sizes were attenuated toward the null. [23] [24] [25] Recent evaluations of RCTs have found that almost half of the publications report subgroup analyses. 8, 9 Furthermore, onethird of RCTs that claimed a subgroup effect for a primary outcome reported a corresponding interaction P value or information that allowed for calculation of the P value for the primary outcome. 9 We found that less than one-third (33 of 14 Previous research suggests that more than one-third of published reanalyses of RCTs lead to different conclusions than those presented by original articles. 35 Herein, we provide additional evidence that most subgroup findings reported in abstracts of RCTs are not subsequently corroborated.
Limitations
Our study has some limitations. First, it is possible that the window of opportunity for corroboration was too short for some index articles. While the SATIRE articles were all published in 2007, the DISCO articles with subgroup findings were published between 2002 and 2012. A minimum of 3 to 4 years may not be long enough for a new RCT to publish a corroboration attempt. We acknowledge that it takes time for the research community to digest the findings from individual RCTs and then plan subsequent RCTs that may or may not evaluate the same subgroup analyses. By evaluating the meta-analyses citing the index articles, we expect to have identified the cumulative evidence related to the more recent DISCO publications. Second, when authors of the index articles presented evidence from tests for interaction or qualitatively stated that subgroup differences existed, we did not perform any additional calculations. We relied on the reported data in the index articles for our calculations. Furthermore, when we extracted data and tested for heterogeneity, we used the effect measures provided by the authors. Because tests for interaction are influenced by the effect measures considered, this limitation may have influenced the classification of certain subgroup findings as to their statistical significance. 36 Third, our
Scopus search may not have identified all subgroup corroboration attempts. Some individual trials evaluating subgroup effects may not cite previous articles making the same subgroup claims. We believe that our search strategy was able to capture most corroboration attempts that could have occurred after the publication date of the index articles. Our experience suggests that the authors of RCTs should avoid putting too much emphasis on subgroup findings. Research consumers, journal reviewers, and journal editors should be cautious about the credibility of subgroup analyses, even those reported prominently in abstracts. We also found examples of subsequent studies claiming to be corroboration attempts for subgroup findings from previous studies but which actually performed modified corroboration attempts. Interaction tests are sensitive to subgroup definitions (ie, 3 group levels or 2 group levels), the effect estimates used (ie, risk ratios or odds ratios), and the exact measurements used for the subgroup or outcome variables. When subsequent studies modify subgroup analyses, they increase the chances of spurious findings and lead research consumers to believe subgroup claims that actually lack adequate support.
Conclusions
Subgroup claims reported in the abstracts of RCTs are often vague, unaccompanied by information pertinent to a test for a significant interaction effect, and unclear regarding prespecification. Our results support the notion that individual subgroup analyses are often spurious and should be considered hypothesis generating. Furthermore, our research indicates that subsequent meta-analyses and RCTs may rarely attempt to corroborate the subgroup findings prominently reported in RCTs. Moreover, when subgroup corroborations are attempted, the initially observed subgroup differences are not demonstrated again. Subgroup analyses in randomized controlled trials (RCTs) are used to determine whether treatment effects vary across certain patient characteristics. 1 Subgroup findings from RCTs may be used to tailor patient care ("stratified medicine"). However, spurious subgroup effects can lead to the withholding of treatment, or the provision of incorrect, ineffective, or harmful treatments, so it is essential that these effects are corroborated. 2 Subgroup analyses are commonly reported in RCTs, with estimates ranging from 40-65%, 1,3-6 but there are many analytical challenges associated with this statistical approach. [7] [8] [9] [10] [11] Trials often perform multiple subgroup analyses without correcting for multiple testing, thereby increasing the probability of a false positive finding. 2, [7] [8] [9] Furthermore, failure to pre-specify subgroup analyses can lead to selective reporting and the reporting of spurious finding given the multiplicity of subgroup analyses performed. 7 According to a recent evaluation of subgroup claims in RCTs, less than 40% of 207 RCTs reporting subgroup analyses pre-specified subgroup hypotheses. 4 Another study found that among RCTs that included pre-specified subgroup analysis plans in a protocol, the number of reported subgroup analyses reported in the publication matched the number planned in the protocol less than 10% of the time. 5 Studies have shown that only about half of RCTs with subgroup analyses use a statistical test for interaction. 4, 7 Current concerns about the inability to replicate published research and the lack of replication in the biomedical literature highlight the importance of validating previous findings.
12 -14 Although previous empirical evaluations have quantified the number of subgroup claims in RCTs and the study characteristics that may influence the reporting of subgroup analyses, [3] [4] [5] little is known about how frequently subgroup claims are externally validated. Given the importance of applying subgroup information to optimize patient care, the objective of this project is to understand how frequently the most prominent of these claims are validated, i.e. those that appear in the abstracts of papers presenting the results of RCTs.
Aims
Aim 1: To determine how often subgroup claims reported in the abstracts of RCTs are subgroup findings (with formal statistical support).
Aim 2a: To determine how often subsequent RCTs are performed on the same treatment comparison and same disease and outcome when a subgroup finding has been published in the abstract of an RCT and how often these subsequent RCTs corroborate the specific subgroup claim.
Aim 2b: To determine how often meta-analyses citing RCTs with a subgroup claim at the abstract level include an outcome that pertains to corroborating a subgroup claim.
Data sources and Methods
We are using two data sources to identify subgroup claims that have been made in the abstracts of published RCTs:
The DISCO Study
A previous study investigated the agreement between the pre-specification of subgroup analyses at the publication level and the corresponding statements at the protocol level. 5 The authors defined a subgroup as "a subset of all trial participants with distinct characteristics at randomization (for example, age, sex, stage of disease)." Subgroup analyses were defined as "an analysis that explored whether intervention effects (experiment versus control) differed according to these characteristics." 5 For additional definitions and methods, please see the original manuscript. 5 We will scrutinize the abstracts of these 86 publications and independently identify the articles in which a claim for a subgroup difference is made in the abstract of the paper After contacting the authors about their study, they shared the following data for the 86 articles they established as having made subgroup claims: author, journal, year of publication, first page of publication, patients randomized, setting (multicenter trial, single center trial), design (parallel, cross-over), label (non-inf/equiv trial, superiority trial, unclear), unit of randomization, journal impact (low, high), industry sponsored (yes, no), medical field, primary outcome significant, subgroup analysis pre-specified in publication, ad hoc subgroup analysis conducted, power calculation for subgroup analysis provided, subgroup hypothesis provided in publication, anticipated direction of subgroup effect provided in publication, interaction term reported, number of subgroup analyses reported, any subgroup claim in publication 2. The SATIRE Group A second study group characterized the analysis, reporting, and claim of subgroup effects in randomized trials. The Subgroup Analysis of Trials Is Rarely Easy (SATIRE) group conducted a systematic review of 464 randomized controlled human trials published in 2007. 3, 4, 15 The authors defined a subgroup as "a subset of a trial population that is identified on the basis of a patient or intervention characteristic that is either measured at baseline or after randomization." They defined a subgroup analysis as "a statistical analysis that explores whether effects of the intervention (i.e. experiment versus control) differ according to status of a subgroup variable. This includes a case in which investigators report a main result and analyze only a subset of patients." In the study protocol, a subgroup effect was defined as "a difference in the magnitude of a treatment effect across subgroups of a study population. The null hypothesis for a test of a subgroup effect (i.e. subgroup hypothesis) is that there is no difference in the magnitude of a treatment effect across subgroups." For additional definitions, please see the original study protocol. 4, 15 From the 207 RCTs with subgroup analyses, the SATIRE group sent us a list of 83 studies that made subgroup claims. We will scrutinize the abstracts of these 83 publications and independently identify the articles in which a claim for a subgroup difference is made in the abstract of the paper.
Definitions
The RCTs previously established as making subgroup claims in these two previous empirical evaluations will form the basis of our empirical evaluation (hereafter referred to as "index articles"). Subgroup claims with clear evidence of statistical heterogeneity (P < 0.05) across subgroup levels will be referred to as "subgroup findings." We will use the same definitions of subgroup, subgroup effect, and subgroup analyses as the SATIRE study. 15 
Review process
For the index articles, two reviewers (JDW, PGS) will independently determine the subset of the articles that make explicit subgroup claims at the abstract level. In cases where an ambiguous subgroup claim is made at the abstract level (e.g., where a subgroup difference is mentioned but an outcome has not been specified), we will consult the full text of the article to identify all potentially relevant subgroup findings that fit within the scope of the abstract level claim.
For each subgroup claim at the abstract level, we will determine whether a significant P-value (P < 0.05) is reported from a test for interaction. For claims without clear evidence of statistical heterogeneity, we will extract the relative or absolute effect sizes, confidence intervals, standard errors, or any other available data that can be used to calculate subgroup-level effect sizes and standard errors. The subgroup level effect sizes and standard errors will be entered into R (version 3.2.3) and the metafor package will be used to formally test for heterogeneity. A P-value less than 0.05 from Cochran's Q test will be used to determine the presence of heterogeneity.
We will record the total number of subgroup claims, the total number of claims where a P-value is reported from a test for interaction, the total number of claims where a significant P-value (P < 0.05) is reported from a test for interaction, and the total number of claims with a significant P-value (P < 0.05) based on calculations. The number of studies with at least one finding will also be recorded.
We will record the first author, year of publication, and journal for each subgroup finding. We will also extract the compared interventions and population (disease/condition) assessed as well as the outcome pertaining to that subgroup claim.
Scopus will be used to scrutinize all citations to each of the eligible index articles with at least one subgroup finding from November to July 2016 (latest search). After recording the total number of citations, we will scan the title and abstract of all citing articles to determine the citing RCTs and meta-analyses. All RCTs and meta-analyses will be downloaded and screened at the full-text for any discussion related to the subgroup findings of interest. We will also record the date of the most recent citing metaanalysis that includes the index RCT in its calculations and the search date of the metaanalysis, when available. Any uncertainties will be discussed in detail with additional reviewers (JFT, KLS, JPAI).
For index articles where we do locate any citing meta-analyses, we will consider the date of the most recent meta-analysis that includes the index RCT in its calculations as the latest time on which we have information on whether a subgroup claim has been validated or not (e.g. if the index RCT was published in 2007, and a citing meta-analysis is published in 2014, with the search date of the meta-analysis being December 2011, then we will consider the literature scanned until December 2011). For these cases, we will perform PubMed searches to identify if any more recent randomized trials exist that examine the same comparison of interventions for the same disease. Search strategies will use the Cochrane Library search string for identifying RCTs coupled with the names of the compared interventions and disease/condition and limited to the time after the publication of the meta-analyses.
Data Abstraction
For RCTs and SR/meta-analyses that assess the subgroup claim from the index article, we will extract the following information:
• First author, journal, year of publication
• Whether any author of the index article with a subgroup finding is also an author of the citing RCT, meta-analysis, or systematic review.
For any eligible meta-analyses, we will consider a subgroup analysis for the main finding as having been reported if the authors report a subgroup-level average effect size for the same intervention(s), outcome(s) and study population(s) as the index article. In particular, we will look for evidence of a subgroup effect included in a forest plot. For eligible articles, we will also record the total number of studies and total number of participants included in the subgroup effect calculation, the total number of studies included in the calculation of the average effect size at the subgroup level were published after the index study, the summary effect size and 95% CI by fixed effects and by random effects in each pertinent subgroup level so as to be able to compare against the data on the subgroup difference in the index study.
For any eligible RCTs, we will extract if the authors report an estimate and an associated confidence interval or a P-value for the effect in each pertinent subgroup level and the difference between the subgroups, if the authors report the results from an interaction test, if the P value for the interaction test is statistically significant at the 0.05 level, and if the authors state that they performed the subgroup analysis, but do not report any of the data discussed above.
We will compare the subgroup difference in the index study against the subgroup difference seen in subsequent RCTs and/or meta-analyses. The index subgroup effect and the subsequent evidence effect will be compared in terms of direction of effect and magnitude of effect.
Additional definitions and methods (updated after initial study protocol)
Definitions
We will use the same definition of a "subgroup" as both the SATIRE 3,15 and DISCO 5 study groups. We defined a subgroup effect as "claimed" if, at the abstract of the paper, there was either a clear or an implied statement that the effects of an intervention (i.e., experiment versus control) differed according to the presence of a subgroup variable. We will regard a subgroup claim as reported in the abstract if one or more of the following are included: a statistically significant result from a test for interaction; a statement about a possible effect in one or more subgroup levels and not others (or a difference in effect estimates of different subgroups), a statement that a subgroup analysis had been undertaken that resulted in subgroup differences, or an effect estimate for one or more subgroups. We will regard the following as being a "null claim" and not a subgroup claim: a statement that an intervention effect did not differ, or was consistent, between or among subgroup levels. The RCTs from the DISCO and SATIRE studies classified as including a subgroup claim in the abstract will be referred to as "index articles". We further defined a "subgroup finding" as a subgroup claim with evidence of statistically significant heterogeneity (P < 0.05) across subgroup levels from an interaction test or where the authors qualitatively implied that there was evidence of statistical heterogeneity. We defined a "pure corroboration attempt" as a subsequent RCT or metaanalyses with an analysis for the exact same subgroup finding(s) as reported in the index article (i.e., for the same subgroup levels, intervention(s), outcome(s), and study population). A subgroup finding will be considered corroborated if a subsequent RCT or meta-analysis has evidence of statistically significant heterogeneity across subgroup levels from an interaction test and if the subgroup-level effect sizes are in the same direction as those reported in the index article. We defined statistical significance as a Pvalue < 0.05.
Methods
Article screening
Two reviewers (JDW, PGS) will independently screen all index articles provided by the SATIRE and DISCO study groups to determine the subset of the articles that made subgroup claims in the abstract. Three additional reviewers will arbitrate all potential discrepancies (JFT, KS, JPAI). In cases where an ambiguous subgroup claim was made at the abstract level (e.g., where a subgroup difference was mentioned but an outcome has not been specified), we will consult the full text of the article to identify all potentially relevant subgroup findings that fit within the scope of the abstract-level claim.
Evaluation of heterogeneity and tests of interaction
For each subgroup claim in the abstract, we will determine whether a statistically significant P-value is reported from a test for interaction in the abstract or only in the full text. When statistically significant P-values are provided or qualitative statements about a statistically significant subgroup difference are made, we will not perform any additional calculations. For claims without clear evidence of statistical heterogeneity, two reviewers (JDW, PGS) will extract the relative or absolute effect sizes, confidence intervals, standard errors, or any other available data that could be used to calculate subgroup-level effect sizes and standard errors. In cases where the index articles do not provide effect measures for the subgroups of interest, we will use our best judgment to determine whether to calculate a relative or absolute effect measure, depending on the other effect measures reported in the index article. When neither relative or absolute effect measures were reported in the text, we will calculate relative effect measures, since the measure of interaction a multiplicative scale are more often assessed and reported based on logistic and Cox models in randomized studies 16, 17 An online digitizer will be used to extract approximate values from figures when needed. When exact calculations are not possible, two reviewers (KS, JDW) will discuss the information provided and determined if it was possible to approximate the P-value for interaction with enough precision to confidently classify it as significant or not significant. For subgroup findings with at least one corroboration attempt, we extracted the overall treatment effect, the subgroup level effects, and whether the interactions were quantitative (where the size of the effect differs in the subgroups but the direction is the same), or qualitative (where the intervention is beneficial in one subgroup and harmful in another).
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The subgroup-level effect sizes and standard errors for the index articles with subgroup claims will be entered into R (version 3.2.3) and the metafor package was used to formally test for heterogeneity using Cochran's Q-test with DerSimonian and Laird fixed effect weighting. When index articles reported hazard ratios, we used RevMan (version 5.4) to formally test for heterogeneity. A third investigator (KS) will review all of the subgroup claim classifications and re-evaluate the test for interactions applying the Altman and Bland method. 18 
Data extraction
For each index article with at least one subgroup claim in the abstract, we will record the first author, year of publication, journal, and sample size randomized. We will also extract the compared intervention(s), population assessed, and the outcome(s) pertaining to each individual subgroup claim. We will note the total number of subgroup claims, the number of claims where a P-value was provided from a test for interaction, the number of claims made in the abstracts of papers where a statistically significant P-value from a test for interaction was reported, the total number of claims where there was not enough information provided in the full text to formally test for subgroup heterogeneity, the total number of claims where there was a qualitative statement in the full text indicating that the subgroup claim was a subgroup finding (e.g., "the interaction term was statistically significant"), and the total number of subgroup findings based on our calculations using the metafor package in R or RevMan.
Evaluation of subgroup finding corroboration
We will use Scopus between November 2015 and July 2016 (all searches updated July 2016) to search for all English language reviews and research articles citing each of the eligible index articles with at least one subgroup finding. One reviewer (JDW) screened the title and abstract of all citing articles to determine the citing RCTs and meta-analyses. All RCTs and meta-analyses were downloaded and screened by two reviewers (JDW, PGS) for evidence of subgroup corroboration attempts. Three additional investigators (JFT, KS, JPA) will arbitrate any uncertainties.
Extractions for meta-analyses and RCTs with corroboration attempts
For individual RCTs and meta-analyses that evaluated the subgroup finding from the index article, we will extract the first author, journal, year of publication, and whether there is any overlap in authorship between the index article and a citing RCT or metaanalysis. When there are several meta-analyses and RCTs on the same corroboration, we will select the most inclusive one.
For any meta-analysis citing an index article with a subgroup finding, we will look for evidence of a subgroup effect included in a forest plot. When available, we will extract the number of studies and number of participants included in the subgroup effect calculation, the number of studies included in the calculation of the average effect size at the subgroup level that were published after the index study, and the summary effect size and 95% CI by fixed effects or by random effects in each pertinent subgroup level. In meta-analyses without detailed information about the evaluation of the subgroup finding, we will describe what information was provided related to the corroboration attempt.
For any subsequent RCT evaluating a subgroup finding established by the index article it was citing, we will look for evidence of a test for interaction and whether the results were statistically significant. We will also note whether the authors stated that they had performed the subgroup analysis, but did not report any additional data.
eText. Additional information about subgroup corroborations
Dexamethasone for suspected bacterial meningitis (BM)
In the 2007 index article comparing dexamethasone with placebo among patients with suspected bacterial meningitis (BM), the authors included a pre-specified subgroup analysis comparing the relative risk of death at 1 month grouped according to diagnosis (definite versus probable bacterial meningitis (BM)). 19 A statistically significant P-value for heterogeneity of the treatment effect was provided in the text, based on a Cox regression model with interaction terms (P = 0.01). The index article implied that there was a qualitative interaction, with lower risk of death at 1 month for patients with definite BM (relative risk 0.43 (95% CI 0.20 to 0.94) and a possibly increased risk of death for patients with probable BM (relative risk 2.65 (95% CI 0.73 to 9.63)). The reported overall relative risk was 0.79 (95% CI 0.45 to 1.39). The study only provided relative risks, total counts for both subgroup levels combined, and Kaplan-Meier (KM) survival curves according to the subgroup levels. Two meta-analyses made full corroboration attempts. In a 2010 meta-analysis 20 , only individual patient data from five randomized, double-blind, placebo-controlled trials were used to establish whether any subgroups of patients with acute BM might benefit from adjunctive dexamethasone. The authors only provided combined odds ratios, using Mantel-Haenszel statistics, and a P-value for the test for subgroup differences (P = 0.23), but did not include any study-level data. Since only pooled odds ratios were provided, we compared the results from the 2010 metaanalysis to the odds ratio for the index article from the forest plot provided by the older 2009 meta-analysis 21 (definite BM: odds ratio 0.46 (95% CI 0.19 to 1.09), probable BM: odds ratio 1.47 (95% CI 0.46 to 4.67); interaction P = 0.1166). This suggested that the subgroup claim from the index article was a non-statistically significant qualitative interaction, when odds ratios are used instead of relative risks. When all of the 2010 meta-analysis data were considered, the subgroup level effect measures were attenuated (definite BM: odds ratio 0.90 (95% CI 0.72 to 1.14), probable BM: odds ratio 1.29 (95% CI 0.75 to 2.21) with interaction P = 0.28). There was also no evidence of an overall treatment effect (odds ratio 0.95 (95% CI 0.77 to 1.17). Among the three individual RCTs included in the earlier meta-analysis, none of the interaction P-values were statistically significant.
Intravenous cooling for nontraumatic out-of-hospital cardiac arrest
In the 2007 index article comparing standard care with intravenous cooling to standard care without intravenous cooling among patients resuscitated by paramedics for nontraumatic out-of-hospital cardiac arrest, the authors reported that the secondary outcome of awakening tended towards improvement in ventricular fibrillation (VF) patients versus non-VF patients randomized to in-field cooling. 22 A subsequent RCT, with at least one of the same co-authors, also included information for the outcome of awakening, but there was no evidence of an interaction test and there were no differences between the VF and non-VF subgroups.
In the index article comparing the 18-month outcomes of N-terminal BNP-guided versus symptom guided heart failure (HF) therapy, the authors reported that HF therapy guided by N-terminal BNP improved outcomes in patients aged 60 to 75 years but not in patients older than 75 years. 24 Evidence from tests for interaction (from Cox regression models adjusted for baseline characteristics) were provided for the outcomes of survival free of any hospitalization (interaction P = 0.02), mortality (interaction P = 0.01), and survival free of hospitalization for HF (interaction P = 0.01). Hazard ratio's (HR) for overall survival were presented and indicated a quantitative interaction (Age <75 years HR = 0.41 (95% CI 0.19 to 0.87) versus ≥75 years HR = 0.88 (95% CI 0.54 to 1.44)). We when reevaluated subgroup heterogeneity using inverse variance fixed effects weighting, there was actually no evidence of a statistically significant quantitative interaction (P = 0.10). The overall treatment effect for the outcome of overall survival indicated a nonstatistically significant HR that favors N-Terminal BNP-Guided Therapy over SymptomGuided Therapy (HR = 0.70 (95% CI 0.47 to 1.06)). The most recent meta-analysis 25 from 2015 that focused specifically on the effects of N-terminal BNP-guided therapy on outcomes in subgroups based on individual patient data provided summary HRs and 95% CIs for both age groups and a non-statistically significant P-value from a test for interaction for the outcome of mortality (<75 years: HR 0.68 (95% CI 0.48 to 0.96), ≥75 years: HR 0.87 (95% CI 0.65 to 1.16); interaction P = 0.22). The authors did not include a forest plot with individual trial data. Both subgroup level effect measures were attenuated towards the null HR value of 1.0. When we calculated the overall HR, we found a marginal beneficial treatment effect (HR 0.78 (0.62 to 1.10)).
In an older meta-analysis 26 from a similar group of authors, a statistically significant interaction between age and treatment efficacy for mortality was reported (<75 years: HR 0.62 (0.45 to 0.85), ≥75 years: HR 0.98 (0.75 to 1.3); interaction P = 0.028). While the authors of the meta-analysis also stated that there was also no statistically significant interaction with age for the outcome of heart failure hospitalizations, both of these corroboration attempts cannot be considered "pure" because the meta-analysis also included patients with LVEF >45% while the index article excluded these patients. In a meta-analysis 27 published in 2015, subgroup analyses were performed for all-cause mortality, all-cause hospitalization, and heart failure related hospitalization, but the age groups were based on different cut-off values (<72 years versus ≥72 years of age). In a meta-analysis 28 from 2013, a separate subgroup analysis was performed for the same age groups, but based on a composite outcome of all-cause mortality and HF-related hospitalization. Lastly, in a 5-year follow-up from the index study, the long-term effects of N-terminal BNP-guided therapy were still more favorable in patients aged 60 to 74 years, however there was no evidence of a statistically significant interaction for hospitalfree survival, HF hospital-free survival, and overall survival. 29 Group therapy for metastatic or locally recurrent breast cancer
In the 2007 index article comparing supportive expressive group therapy (education materials plus weekly supportive expressive group therapy) for the primary outcome of survival among women with confirmed metastatic or locally recurrent breast cancer, the authors reported that a hormone estrogen receptor (ER) status (positive versus negative) by treatment interaction was statistically significant (P = 0.002), indicating that ERnegative participants randomized to treatment survived longer. 30 One commentary published in 2008 attempted to corroborate the subgroup finding using data from another RCT. 31 The authors of the commentary stated that the subgroup results from the index RCT were based on a small subsample (n = 25 ER-negative women), and an exact replication with a larger sample size (n = 70 ER-negative women) did not find a significant receptor status by treatment interaction (P = 0.71). The authors concluded that the subgroup results from the index article were likely a chance finding. 31 Low-glycemic load for young adults with obesity A SATIRE RCT compared low-glycemic load (40% carbohydrate and 35% fat) and lowfat (55% carbohydrate and 20% fat) diets for the primary outcomes of body weight, body fat percentage, and cardiovascular disease risk factors among young adults with obesity. 32 Statistically significant interactions for insulin concentration at 30 minutes during a 75-gram oral glucose tolerance test (above or below the median of 57.5 uIU/ml) by diet for the outcomes of body weight (P=0.02) and body fat percentage at 18 months (P = 0.01) were reported. A few subsequent RCTs tested for a diet by insulin status interaction for weight loss. 33, 34 However, none of these RCTs used insulin concentration at 30 minutes as the measurement of insulin status.
Epoetin alfa to prevent red-cell transfusion
In the topic where epoetin alfa was compared to placebo for the primary outcome of percentage of patients who received a red-cell transfusion, the authors reported two similar subgroup findings without providing P-values from interaction tests. 35 Based on our own calculations using data extracted from the text to perform the test for heterogeneity, mortality at day 140 had a statistically significant P-value (0.03) and mortality at day 29 had a non-statistically significant P-value of 0.05. Two meta-analyses from 2007 36 and 2013 37 had subgroup analyses that were partial corroboration attempts for the outcome of mortality, but they both used data at day 29 instead of day 140. In the index RCT, the a priori established subgroup analyses were based on three mutually exclusive admission subgroups (trauma, surgical non-trauma, and medical non-trauma patients). Both meta-analyses attempting to corroborate the subgroup finding from the index article based their calculations on a binary comparison of trauma versus nontrauma patients. While the 2013 meta-analysis reported a statistically significant P-value (0.002) for subgroup differences from a post hoc analysis of trauma versus non-trauma patients, there was no forest plot, study level effect measures, or further information about the studies contributing data to the non-trauma subgroup level. 37 Among the five studies for the trauma subgroup, one was a Russian article that could not be located, one was an earlier RCT with the same first author as the first author of the index article reporting the subgroup finding, one was an abstract, one was a matched case control study, and one was an RCT from 2008 that only included trauma patients. 37 The 2007 meta-analysis attempting to corroborate the subgroup finding from the index article provided an effect size for the trauma subgroup, a P-value from a test for heterogeneity was not reported. Lastly, this meta-analysis only included data from the two RCTs with the same first author as the first of the index article. 36 Both meta-analyses warned that the results from the subgroup analyses were driven by the data from the two RCTs by the first author of the index article and that the results should be interpreted with caution. 36, 37 Escalated-dosing for acute myeloid leukemia or high-risk refractory anemia
In the index article comparing cytarabine plus daunorubicin at the conventional-dose or at an escalated-dose among patients newly diagnosed with acute myeloid leukemia or highrisk refractory anemia, the authors reported that patients in the escalated-treatment group who were 60 to 65 years of age had higher rates of remission, event-free survival, and overall survival compared with the patients in the same age group who received the conventional dose. 38 Although this was an unclear claim at the abstract level, the authors specified that post hoc tests for interaction were performed according to age in the methods (60-65 years, 66-70 years, >70 years). While a significant p-value for interaction was provided for rates of complete remission, the authors included a qualitative statement that tests for an interaction between age and treatment were also significant for overall survival and the primary outcome, event-free survival. The only meta-analysis that investigated the subgroup finding from the index article used a dichotomous age subgroup (>65 years versus <65 years) and could not be considered a full corroboration attempt. 39 Furthermore, there was one trial included in this meta-analysis that contributed data to >65 years age group for the outcomes of complete remission and overall survival. 
